Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$42.74 USD
+0.38 (0.90%)
Updated Sep 19, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Ionis Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,331 | 1,987 | 2,115 | 1,892 | 2,500 |
Receivables | 98 | 26 | 62 | 76 | 63 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 28 | 22 | 25 | 22 | 18 |
Other Current Assets | 184 | 168 | 143 | 140 | 140 |
Total Current Assets | 2,642 | 2,203 | 2,345 | 2,131 | 2,721 |
Net Property & Equipment | 71 | 74 | 178 | 181 | 154 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 306 |
Intangibles | 0 | 0 | 29 | 28 | 26 |
Deposits & Other Assets | 105 | 75 | 60 | 50 | 28 |
Total Assets | 2,990 | 2,534 | 2,612 | 2,390 | 3,233 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 26 | 18 | 12 | 17 | 16 |
Current Portion Long-Term Debt | 44 | 0 | 4 | 300 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 216 | 189 | 127 | 156 | 104 |
Income Taxes Payable | 2 | 6 | 0 | 1 | 33 |
Other Current Liabilities | 160 | 98 | 98 | 108 | 118 |
Total Current Liabilities | 448 | 312 | 241 | 583 | 273 |
Mortgages | 0 | 9 | 60 | 60 | 60 |
Deferred Taxes/Income | 241 | 288 | 352 | 424 | 490 |
Convertible Debt | 1,188 | 1,167 | 1,161 | 456 | 710 |
Long-Term Debt | 42 | 7 | 26 | 23 | 16 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 514 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,603 | 1,961 | 1,840 | 1,546 | 1,549 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,215 | 2,060 | 1,964 | 2,114 | 2,204 |
Retained Earnings | -1,796 | -1,430 | -1,160 | -1,249 | -708 |
Other Equity | -33 | -57 | -33 | -21 | 188 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 387 | 573 | 772 | 843 | 1,685 |
Total Liabilities & Shareholder's Equity | 2,990 | 2,534 | 2,612 | 2,390 | 3,233 |
Total Common Equity | 387 | 573 | 772 | 843 | 1,685 |
Shares Outstanding | 143.40 | 142.00 | 141.20 | 139.80 | 140.60 |
Book Value Per Share | 2.70 | 4.03 | 5.47 | 6.03 | 11.98 |
Fiscal Year End for Ionis Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,079 | 2,206 | 2,331 | 2,236 | 2,385 |
Receivables | 27 | 5 | 98 | 142 | 28 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 29 | 30 | 28 | 26 | 26 |
Other Current Assets | 195 | 174 | 184 | 181 | 178 |
Total Current Assets | 2,329 | 2,416 | 2,642 | 2,585 | 2,617 |
Net Property & Equipment | 76 | 73 | 71 | 71 | 92 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 119 | 106 | 105 | 104 | 86 |
Total Assets | 2,691 | 2,764 | 2,990 | 2,934 | 2,971 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 44 | 44 | 0 | 0 | 0 |
Accounts Payable | 9 | 13 | 26 | 6 | 24 |
Current Portion Long-Term Debt | 0 | 0 | 44 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 149 | 128 | 216 | 153 | 134 |
Income Taxes Payable | 0 | 2 | 2 | 31 | 25 |
Other Current Liabilities | 103 | 140 | 160 | 215 | 105 |
Total Current Liabilities | 306 | 328 | 448 | 404 | 288 |
Mortgages | 42 | 42 | 0 | 49 | 0 |
Deferred Taxes/Income | 189 | 215 | 241 | 249 | 254 |
Convertible Debt | 1,191 | 1,189 | 1,188 | 1,230 | 1,299 |
Long-Term Debt | 0 | 0 | 42 | 0 | 16 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 534 | 514 | 513 | 510 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,427 | 2,467 | 2,603 | 2,619 | 2,543 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,303 | 2,270 | 2,215 | 2,148 | 2,118 |
Retained Earnings | -2,005 | -1,939 | -1,796 | -1,787 | -1,639 |
Other Equity | -35 | -35 | -33 | -46 | -51 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 264 | 297 | 387 | 315 | 428 |
Total Liabilities & Shareholder's Equity | 2,691 | 2,764 | 2,990 | 2,934 | 2,971 |
Total Common Equity | 264 | 297 | 387 | 315 | 428 |
Shares Outstanding | 146.20 | 145.70 | 143.40 | 143.40 | 143.10 |
Book Value Per Share | 1.80 | 2.04 | 2.70 | 2.20 | 2.99 |